tirzepatide surmount-1 weight loss percent 72 weeks results for the Maintenance of Body Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity GLP-1R Agonists for Weight Loss

Some clinicians find that patients can maintain results on mid-range tirzepatide doses after losing weight at higher doses

Final Thoughts GLP-1 medications have transformed how we treat obesity: Semaglutide broke ground with ~15% average weight loss

When you enroll with us, our clinical team carefully evaluates your progress

Its result of 28.3% over 80 weeks is meaningfully higher than standard Wegovy, higher than Wegovy HD, and higher than the current Zepbound

Dosing and administration Retatrutide is administered subcutaneously once weekly, with dosing regimens ranging from 1 mg to 12 mg

Great product and service The entire process was super quick including shipping